Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.
Also called NCT03071263
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 295 participants
- Sponsor
- Registry
-
NCT03071263 -
2016-002657-38
-
- Other papers using this trial's data
- Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Croatia, Georgia, Germany, Hungary, South Africa, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03071263. Randomized; quadruple masking; primary purpose treatment. Start 2017-01-23 (actual); primary completion 2018-11-27 (actual). Results posted on 2020-01-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
- Acronym
- AMBER
- Condition
- Hyperkalemia
- Condition
- Resistant Hypertension
- Intervention (Drug)
- Patiromer
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Spironolactone
- Lead sponsor
- Relypsa, Inc.
Record details
- Record id
cardio:ct-nct03071263- Content hash
fed3e2147a11a8f18a7199b7271d2be8ec78f2245f697792582f7aea2c3ceb2f